Solventum (SOLV) investor relations material

Transformation progress and strategic priorities

• Transformation structured in three phases: mission/talent/culture and Separation, strategic focus and commercial restructuring, and portfolio transformation with ongoing M&A and SKU rationalization.

• Separation from the former parent is about halfway complete, with full completion targeted by end of 2026.

• Strategic focus includes prioritizing growth markets, restructuring sales, and aligning innovation to growth drivers, resulting in tripled growth rate from 2024 to 2025.

• Portfolio transformation includes divestitures, tuck-in acquisitions, and ongoing assessment of business fit.

• Culture shift emphasizes decentralized decision-making, accountability, and high engagement, supported by above-benchmark engagement survey results.

Financial performance and guidance

• Achieved above 3% organic growth in 2025, exceeding initial guidance, driven by successful commercial restructuring and innovation.

• 2026 revenue growth guidance set at 2%-3% (or 3%-4% ex-SKU reductions), with key assumptions based on continued commercial enhancements and innovation.

• Margin expansion targeted at 21%-21.5% for 2026, overcoming tariff headwinds through sales leverage and efficiency programs.

• Free cash flow in 2026 impacted by Separation and divestiture costs, but expected to approach $1 billion by 2027-2028 as these items subside.

• Long-term plan targets 4%-5% organic growth and 23%-25% operating margin by 2028, with confidence supported by faster-than-expected progress.

Segment and market insights

• HIS segment expected to improve, leveraging AI for Autonomous Coding and revenue cycle management, with proprietary data and algorithms as differentiators.

• Dental segment showing signs of stabilization and improvement, with growth driven primarily by new product innovation.

• MedSurg segment focuses on three growth drivers: negative pressure wound therapy (especially single-use), IV site management, and sterilization assurance, with strong recent and upcoming product launches.

• Negative pressure wound therapy market remains under-penetrated, with single-use products offering double-digit growth and mix benefits.

• Revenue cycle management growth driven by 360 Encompass System, Autonomous Coding, and international expansion.